Status:
UNKNOWN
Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
Lead Sponsor:
Royal Free Hospital NHS Foundation Trust
Conditions:
Haemophilia
Eligibility:
MALE
18+ years
Brief Summary
Severe haemophilia A and B (SHA, SHB) are X - linked inherited bleeding disorders, characterised by factor VIII and IX levels of \<1 IU/dL respectively. The mainstay of treatment in SHA and SHB is rep...
Eligibility Criteria
Inclusion
- Patients
- Patients with haemophilia A or B (baseline FVIII/FIX level \<30%)
- Age ≥ 18 years
- Written informed consent in accordance with local and institutional guidelines.
Exclusion
- 1\. Patients currently enrolled into a clinical trial of investigational medicinal product for haemophilia.
- Healthy Volunteers
- Inclusion Criteria:
- Currently not receiving any antiplatelet or anticoagulant therapy or other drugs that can affect the coagulation system.
- Age ≥ 18 years
- Written informed consent in accordance with local and institutional guidelines.
Key Trial Info
Start Date :
September 19 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 2 2020
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT03287999
Start Date
September 19 2017
End Date
October 2 2020
Last Update
March 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Free Hospital
London, United Kingdom